Diligence. Following the successful completion by ​ of the Initial Development Activities in accordance with the Initial Development Plan and Budget and [[Organization A:Organization]] proceeding with the In-Licensing, [[Organization A:Organization]] shall use Commercially Reasonable Efforts to obtain all Regulatory Approvals for the initial Licensed Product containing or comprising the Lead Compound for the Initial Indications in accordance with the applicable Development Plan.

Regulatory Diligence. ​ shall use Commercially Reasonable Efforts in undertaking the Development activities (including Initial Development Activities) for the initial Licensed Product containing or comprising the Lead Compound for the Initial Indications in those countries in the Territory set forth in the Initial Development Plan and Budget. ​ acknowledges that the exercise of its Commercially Reasonable Efforts as set forth in this Section 3.1.3 means the delivery by ​ to [[Organization A:Organization]] of the # RA Complete Data Package by the date set forth in the Initial Development Plan and Budget, and # SLE Complete Data Package by the date set forth in the Initial Development Plan and Budget, in each case, unless otherwise mutually agreed to by the Parties.

Diligence. After [[Organization A:Organization]] proceeds with the In-Licensing, [[Organization A:Organization]] shall use Commercially Reasonable Efforts to Commercialize a Licensed Product for the Initial Indications in each Major Market following receipt of Regulatory Approval therefor in each such Major Market. For purposes of clarity, [[Organization A:Organization]] shall not be obligated to Commercialize more than one (1) Licensed Product or any Licensed Product for more than the Initial Indications in any Major Market. ​ acknowledges and agrees that, in addition to the foregoing, # the Commercialization of Licensed Product may be delayed, suspended or otherwise modified by [[Organization A:Organization]] in response to circumstances outside the reasonable control of [[Organization A:Organization]], including force majeure events and serious safety and efficacy issues, and # [[Organization A:Organization]] shall have the right to satisfy its diligence obligations under this Section 4.2 through its Affiliates or Sublicensees. If [[Organization A:Organization]] decides to discontinue the Development or Commercialization of a Licensed Compound or Licensed Product in favor of another Licensed Compound or Licensed Product, its obligations under this Section 4.2 shall cease with respect to such initial Licensed Compound or Licensed Product in favor of such other Licensed Compound or Licensed Product. If at any time ​ has a reasonable basis to believe that [[Organization A:Organization]] is in material breach of its obligations under this Section 4.2, then ​ shall so notify [[Organization A:Organization]], specifying the basis for its belief, and the Parties shall meet within […​…] after such notice to discuss in good faith ​’s concerns and [[Organization A:Organization]]’s Commercialization plans with respect to the Licensed Product.